Submission of Nidlegy marketing authorisation application validated by EMA
July 6, 2024
Source: drugdu
102
Philogen and Sun Pharmaceutical Industries (“Sun Pharma”) announces that on June 20 the European Medicines Agency (EMA) validated the submission of the Marketing Authorisation Application (MAA) for Nidlegy , which was finalised on June 3 2024.
“The validation of the dossier by EMA represents the first important milestone for the MAA review process,” commented Dario Neri, chief executive officer and chief scientific officer at Philogen. “Our group is committed to working with EMA throughout the review process with the goal of making Nidlegy available to patients in need.”
Nidlegy is partnered with Sun Pharma for the treatment of Skin Cancers in Europe, New Zealand and Australia.
The data of the Phase III Nidlegy trial are expected to be published in a peer-reviewed scientific journal in 2024.
https://sunpharma.com/wp-content/uploads/2024/07/Press-Release-Validation-of-Nidlegy%E2%84%A2-Marketing-Authorization-Application-Submission-by-EMA.pdf
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Merck’s long-acting RSV antibody therapy submitted for marketing application December 23, 2024
- After buying four years of performance, Kangchen Pharmaceuticals finally suffered a goodwill explosion December 23, 2024
- The first wholly foreign-owned tertiary general hospital was established in Tianjin December 23, 2024
- Legendary liver disease drug falls from the altar December 23, 2024
- Yingtai Medical acquires Weiqiang Medical December 21, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
